Arabic Arabic English English French French German German

BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline

BioCryst Pharmaceuticals, Inc. announced that hereditary angioedema patients who were randomized to receive 150 mg of oral, once-daily ORLADEYO® at the start of the APeX-2 trial had an 80 percent average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Effects of cultured Cordycep militaris on sexual performance and erectile function in streptozotocin-induced diabetes.

Next Post

New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology Hybrid Congress

Related Posts